Delving into the Latest Updates on BioNTech Research & Development, Inc. with Synapse

Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Open label, nonrandomized, dose-escalation with cohort expansion study of MVT-5873/MVT-1075 in subjects with previously treated, Carbohydrate Antigen 19-9 (CA19-9) positive malignancies (e.g., pancreatic adenocarcinoma).

开始日期2017-06-01

申办/合作机构

BioNTech Research & Development, Inc.

NCT02687230 / Terminated临床1期

Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

开始日期2016-07-11

申办/合作机构

BioNTech Research & Development, Inc.

[+1]

NCT02672917 / Active, not recruiting临床1期

Phase 1 Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) With Expansion in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.

开始日期2016-01-01

申办/合作机构

BioNTech Research & Development, Inc.

100 项与 BioNTech Research & Development, Inc. 相关的临床结果

登录后查看更多信息

0 项与 BioNTech Research & Development, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 BioNTech Research & Development, Inc. 相关的药物交易

登录后查看更多信息

100 项与 BioNTech Research & Development, Inc. 相关的转化医学

登录后查看更多信息